Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.62 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21820855 | 0.85 | MAPK1 (0.49) | MAPK1BRD4SYKCHEK1PIM1 | |
| SCHEMBL7950769 | 0.80 | MAPK1 (0.39) | MAPK1SYKPDK2PDK4JAK3 | |
| SCHEMBL12657766 | 0.80 | MAPK1 (0.67) | MAPK1BRD4CHEK1 | |
| SCHEMBL30258999 | 0.77 | MAPK1 (0.62) | MAPK1BRD4CHEK1 | |
| SCHEMBL21821096 | 0.77 | MAPK1 (0.62) | MAPK1BRD4CHEK1 | |
| SCHEMBL650607 | 0.77 | MAPK1 (0.62) | MAPK1BRD4CHEK1JAK2 | |
| SCHEMBL16946856 | 0.77 | MAPK1 (0.37) | MAPK1SYKPDK2PDK4JAK3 | |
| SCHEMBL29488969 | 0.77 | MAPK1 (1.00) | MAPK1BRD4SYKCHEK1JAK3 | |
| SCHEMBL30259037 | 0.77 | MAPK1 (0.62) | MAPK1BRD4CHEK1JAK2 | |
| SCHEMBL13199608 | 0.77 | JAK2 (0.40) | MAPK1SYKPDK2PDK4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| EP-3317285-B1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-108218873-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-20200085822-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-03-19 | — | — | US | disclosed |
| US-9309250-B2 | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309250-B2 | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150376187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| US-9096602-B2 | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096602-B2 | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-04 | — | — | US | disclosed |
| US-8822469-B2 | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822469-B2 | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130034616-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130018035-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130017273-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | MAPK1 122/4885BRD4 1445/4885SYK 495/4885 |
| US-20130018035-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | MAPK1 122/4885BRD4 1445/4885SYK 495/4885 |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | ZC3HAV1, MAVS, POLRMT | MAPK1 2020/4885BRD4 1110/4885SYK 2497/4885 |
| US-20130017273-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | MAPK1 122/4885BRD4 1445/4885SYK 495/4885 |
| US-20130034616-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | MAPK1 122/4885BRD4 1445/4885SYK 495/4885 |
| US-20200085822-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | ZC3HAV1, MAVS, POLRMT | MAPK1 2020/4885BRD4 1110/4885SYK 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.